Podchaser Logo
Home
Park and Sonpavde on Considerations for Enfortumab Vedotin Plus Pembrolizumab in Bladder Cancer

Park and Sonpavde on Considerations for Enfortumab Vedotin Plus Pembrolizumab in Bladder Cancer

Released Thursday, 30th May 2024
Good episode? Give it some love!
Park and Sonpavde on Considerations for Enfortumab Vedotin Plus Pembrolizumab in Bladder Cancer

Park and Sonpavde on Considerations for Enfortumab Vedotin Plus Pembrolizumab in Bladder Cancer

Park and Sonpavde on Considerations for Enfortumab Vedotin Plus Pembrolizumab in Bladder Cancer

Park and Sonpavde on Considerations for Enfortumab Vedotin Plus Pembrolizumab in Bladder Cancer

Thursday, 30th May 2024
Good episode? Give it some love!
Rate Episode

Unlock Episode Insights with

Podchaser Logo PRO

Reach • Demographics • Contacts • More

Pro Features

Audience & Reach for Park and Sonpavde on Considerations for Enfortumab Vedotin Plus Pembrolizumab in Bladder Cancer

See a breakdown of Audience & Reach for Park and Sonpavde on Considerations for Enfortumab Vedotin Plus Pembrolizumab in Bladder Cancer

Unlock Episode Audience & Reach with Podchaser Pro

Brand Safety for Park and Sonpavde on Considerations for Enfortumab Vedotin Plus Pembrolizumab in Bladder Cancer

See Brand Safety for Park and Sonpavde on Considerations for Enfortumab Vedotin Plus Pembrolizumab in Bladder Cancer

Unlock Episode Brand Safety with Podchaser Pro

Ad Rate Card of OncLive® On Air

How much does it cost to advertise on OncLive® On Air?

PlacementCost
Pre-rollAds played before an episode.
Mid-rollAds played during an episode.
Post-rollAds played after an episode.

Frequently Asked Questions about OncLive® On Air

Unlock more with Podchaser Pro

  • Audience Insights
  • Contact Information
  • Demographics
  • Charts
  • Sponsor History
  • and More!
Pro Features